In previous studies on tumor chemotherapy drug resistance, miR-29b was found to reverse Oxa resistance of CRC cells by targeting the SIRT1/ROS/JNK pathway [46], moreover, it can also target FOLR1 to inhibit cell growth of colon cancer cells and increases cell sensitivity to Oxa [47]. This evidence concerns the gene FOLR1 and colonic neoplasm.